Recall Record: Class II Recall: BIOFIRE Respiratory Panel 2.1 (RP2.1) REF 423742 UDI… by BioFire Diagnostics, LLC

Key facts

What consumers should do

Facilities, clinicians, and consumers holding an affected unit or lot of BIOFIRE Respiratory Panel 2.1 (RP2.1) REF 423742 UDI code: 00815381020529 PCR-based multiplexed nucleic acid test, in vitro diagnostic should stop using it for the purpose described in the recall notice and hold remaining stock pending instructions from BioFire Diagnostics, LLC. FDA recall records typically direct the recalling firm to notify known accounts directly with a recall letter describing the specific corrective action -- replacement, field correction, refund, or return. Anyone who received the product through a distributor rather than directly from BioFire Diagnostics, LLC should confirm with their supplier whether their specific lot or unit is on the affected list, since recall notices are lot- or unit-specific and not every unit of a product line is necessarily included. Questions about a specific unit's status should go to BioFire Diagnostics, LLC directly or to the distributor that supplied it; Argus HQ is a public-record aggregator, not the recalling firm, and cannot confirm individual unit status.

What this classification means

A Class II recall is FDA’s middle classification. FDA assigns Class II when use of, or exposure to, the recalled product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote. FDA still requires the recalling firm to notify affected accounts and submit status reports on the correction, though the monitoring intensity is lower than for a Class I recall. FDA's Center for Devices and Radiological Health (for devices) or Center for Drug Evaluation and Research (for drugs) reviews the classification and can require additional corrective action if the initial response is judged insufficient. Because this record is filed as Class II, professionals and consumers handling an affected lot should treat FDA's own classification -- not this page's summary of it -- as the authoritative risk signal. A Class I recall is FDA’s most serious classification. FDA assigns Class I when there is a reasonable probability that use of, or exposure to, the recalled product will cause serious adverse health consequences or death. This classification does not mean harm has already occurred in every case -- it reflects FDA’s assessment of the realistic worst-case risk profile of the defect described in the recall, based on the reason for recall reported by the firm. Class I recalls receive the closest FDA monitoring of the three classes: the recalling firm typically must submit a recall strategy, periodic status reports, and effectiveness checks confirming that the affected lots have actually been removed from distribution or corrected in the field.

BioFire Diagnostics, LLC’s FDA history

Argus HQ has recorded 3 total FDA actions tied to BioFire Diagnostics, LLC: 0 warning letters, 3 recalls, 0 approval records, and 0 Form 483 inspection citations.

Frequently asked questions

Why was BIOFIRE Respiratory Panel 2.1 (RP2.1) REF 423742 UDI code: recalled?

FDA's recall record states the reason as: Due to increase in false negative results

Who should I contact about this recall?

Contact BioFire Diagnostics, LLC directly, or the distributor/pharmacy that supplied the product, to confirm whether your specific lot or unit is affected. Argus HQ aggregates the public FDA recall record and is not the recalling firm.

Has BioFire Diagnostics, LLC had other FDA recalls or enforcement actions?

Yes. Argus HQ has recorded 3 total FDA actions tied to BioFire Diagnostics, LLC, including 3 recalls and 0 warning letters.

What is the FDA recall number for this event?

FDA recall number Z-2936-2026.

Related enforcement actions